Publications by authors named "Changju Qu"

Claim this Profile
S
Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma.
Lingzi Yu, Nana Ping, Rui Zou, Qian Zhu, Junhong Li, Changju Qu

Cancer Immunol Immunother· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of the gut microbiome on lymphoma treatment: current evidence and future therapeutic directions.
Jiajie Tu, Lingzi Yu, Rui Zou, Jiajie He, Changju Qu

Ther Adv Med Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial.
Jia Yin, Qing-Ya Cui, Hai-Ping Dai, Chang-Ju Qu, Zheng Li

J Hematol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosis.
Danqing Kong, Nana Ping, Qian Zhu, Xiao Zhang, Junhong Li, Changju Qu

Front Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects.
Lingzi Yu, Rui Zou, Jiajie He, Changju Qu

Crit Rev Oncol Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computer-aided diagnostic system with automated deep learning method based on the AutoGluon framework improved the diagnostic accuracy of early esophageal cancer.
Xin Gao, Jiaxi Lin, Changju Qu, Chao Wang, Airong Wu

J Gastrointest Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review.
Jiajie He, Rui Zou, Liqing Kang, Lingzi Yu, Peng Wang, Changju Qu

Front Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.
Rui Zou, Xiao Zhou, Hailing Liu, Peng Wang, Fan Xia, Changju Qu

Cancer Res Treat· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma.
Min Hu, Yiduo Ding, Haizhou Zhang, Wei Guo, Yun Li, Changju Qu

Front Pharmacol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
Danqing Kong, Nana Ping, Xin Gao, Rui Zou, Peng Wang, Changju Qu

Front Immunol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma.
Lihong Zhang, Haifei Yang, Chongsheng Qian, Jihao Zhou, Qian Zhu, Changju Qu

Hematology· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual epigenetic agents plus rituximab-gemcitabine-oxaliplatin as salvage treatment in relapsed/refractory diffuse large B-cell lymphoma patients failure of salvage chemotherapy.
Changju Qu, Nana Ping, Danqing Kong, Aining Liu, Hailing Liu

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Changju Qu, Rui Zou, Peng Wang, Qian Zhu, Liqing Kang

Front Immunol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells.
Jingwen Tan, Yujie Jia, Meixia Zhou, Chengcheng Fu, Israth Jahan Tuhin, Changju Qu

J Hematol Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.
Nana Ping, Changju Qu, Mengyun Li, Liqing Kang, Danqin Kong

Ann Transl Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment.
Yun-Ju Ma, Hai-Ping Dai, Qing-Ya Cui, Wei Cui, Wen-Juan Zhu, Chang-Ju Qu

Am J Cancer Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple blood parameters may serve as a warning to immunochemotherapy-related interstitial lung disease in B-cell lymphoma.
Fan Xia, Hailing Liu, Haizhou Zhang, Nana Ping, Peng Wang, Changju Qu

Ann Palliat Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations.
Changju Qu, Yaohua Song, Jia Yin, Yunju Ma, Liqing Kang

Bone Marrow Transplant· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.
Xiaowen Tang, Benigno C Valdez, Yunju Ma, Qianqian Zhang, Changju Qu

Bone Marrow Transplant· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Qingya Cui, Chongsheng Qian, Nan Xu, Liqing Kang, Haiping Dai, Baoquan Song, Changju Qu

J Hematol Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph mixed phenotype acute leukaemia with minimal residual disease.
Danqing Kong, Changju Qu, Haiping Dai, Zheng Li, Jia Yin

Br J Haematol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia.
Yunju Ma, Changju Qu, Haiping Dai, Jia Yin, Zheng Li

Bone Marrow Transplant· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Changju Qu, Nana Ping, Liqing Kang, Hailing Liu, Songbin Qin

J Immunother· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Xiaofei Yang, Haiping Dai, Liqing Kang, Changju Qu, Zheng Li

Hematol Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma.
Caixia Li, Ying Zhang, Changfeng Zhang, Jia Chen, Xiaoyan Lou, Changju Qu

JCI Insight· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis